India May Have Concerns on DowDuPont

(c) Dow Chemicals
(c) Dow Chemicals

Just as news agencies and the CEOs of and DuPont had begun reporting that the merger of the two US chemical powerhouses was close to receiving all regulatory approvals, antitrust authorities in India have announcd they have concerns about the $130 billion deal.

In a statement on Mar. 22, the Competition Commission of India (CCI) said it is “of the prima facie opinion that the proposed combination between Dow Chemical Company and E. I. du Pont de Nemours and Company is likely to have an appreciable adverse effect on competition."

The authority has not been explicit about its concerns but said it has sought public opinion on the deal and has directed the two companies to publish details of their proposed merger.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.